Adagene Revenue 2011-2026 | ADAG

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Adagene

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	10.2 M	701 K	480 K	1.51 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
10.2 M	480 K	3.22 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	257 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	71.5 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Coherus BioSciences CHRS	42.2 M	$ 1.63	-4.4 %	$ 191 M	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 7.83	-5.21 %	$ 214 M	Israel
Esperion Therapeutics ESPR	403 M	$ 3.12	-	$ 649 M	USA
Exelixis EXEL	2.32 B	$ 51.1	-0.37 %	$ 13.9 B	USA
Forte Biosciences FBRX	18 M	$ 23.96	-2.84 %	$ 310 M	USA
Karyopharm Therapeutics KPTI	146 M	$ 8.9	0.56 %	$ 1.08 M	USA
AbCellera Biologics ABCL	75.1 M	$ 4.4	-7.76 %	$ 1.31 B	Canada
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Amphastar Pharmaceuticals AMPH	720 M	$ 17.3	-5.57 %	$ 809 M	USA
BioNTech SE BNTX	482 M	$ 91.99	-0.26 %	$ 22.2 B	Germany
Compugen Ltd. CGEN	6 M	$ 3.03	6.32 %	$ 283 M	Israel
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Gilead Sciences GILD	29.4 B	$ 132.06	-0.74 %	$ 164 B	USA
Genmab A/S GMAB	10.1 B	$ 26.9	1.32 %	$ 1.74 B	Danmark
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	405 K	$ 3.49	-4.12 %	$ 5.75 M	Israel
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
Grifols, S.A. GRFS	7.21 B	$ 7.79	1.04 %	$ 5.29 B	Spain
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Fortress Biotech FBIO	63.3 M	$ 2.3	3.14 %	$ 64.2 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 21.57	-0.55 %	$ 2.74 B	USA
Fennec Pharmaceuticals FENC	44.6 M	$ 9.24	36.48 %	$ 264 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA